CASSS Mass Spec 2025

Schedule a meeting with our team to learn how our platform can support your gene therapy research and development.

We’re excited to present our latest advances in gene therapy quality control:

Monitoring Intact AAV and AAV Building Blocks Through Individual Ion Mass Spectrometry

Our presentation highlights how ImmPro’s automated, high-throughput platform leverages Charge Detection Mass Spectrometry (CDMS) to deliver direct, precise measurements of intact AAV capsids and their building blocks — insights critical to ensuring therapeutic efficacy and meeting regulatory expectations.

ImmPro’s CDMS-based assay uniquely detects and quantifies empty, full, and partially filled AAV capsids by directly measuring individual particle mass, helping gene therapy teams optimize processes and maintain product quality.

Key advantages of our platform:

• Accurate, reproducible measurements validated to ICH Q2(R1) standards

• High-throughput, autonomous operation for efficient workflows

• Minimal sample requirements compared to traditional methods

• Fast turnaround times to support complex DOE studies and tight timelines

By standardizing AAV quality control with robust, mass-based data, ImmPro empowers gene therapy developers to make faster, more confident decisions at every stage — from process development to QC release and stability studies.

If you’re attending CASSS, we’d love to connect with you there. See you in Costa Mesa!